Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026

Core Insights - The Danish drugmaker anticipates a decline in adjusted sales between 5% and 13% at constant exchange rates for 2026, marking a significant reversal from the previous year when sales experienced a growth of 10% [1] Company Performance - The company reported a sales growth of 10% in the previous year, indicating a strong performance prior to the expected decline in 2026 [1] - The projected decline in sales for 2026 suggests potential challenges ahead for the company, contrasting sharply with the growth trend observed last year [1] Market Outlook - The anticipated sales decline reflects broader market conditions and may impact the company's competitive positioning within the pharmaceutical industry [1] - The shift from growth to decline could influence investor sentiment and market expectations regarding the company's future performance [1]